Novo Nordisk

Novo Nordisk A/S leads in diabetes and obesity care, driving growth through a global pipeline of insulin, GLP‑1 therapies and smart delivery systems. The rare disease segment expands its therapeutic footprint, positioning the firm for long‑term upside.

Headquarters: Denmark (DNK)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Manufacturing
Industry: Pharmaceutical Manufacturing

Employees: 78,554
HQ: Bagsvaerd

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
NOVO-B	Novo Nordisk Class A/S Cap: 1783.4B \| P/E: 17.2	EQUITY	CPH	DKK	DK0060534915	Active	📈